The global market for fusion proteins is expected to grow from $36.3 billion in 2025 to reach $64.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2030.
Fusion proteins are an emerging area in protein engineering that combines an antibody with a desirable protein. The primary goals of fusion protein technology are to extend the duration of action and impart higher stability to protein drugs. These products have applications across therapeutic areas, including autoimmune, metabolic, oncologic, ophthalmic and cardiovascular conditions. The commercial success of many fusion proteins is driving the development of biosimilar versions of these proteins. Enbrel, Orencia, Trulicity, Eylea and Arcalyst were some of the best-selling fusion protein drugs in 2024.
According to type, the market is segmented into cytokine traps, peptide-based fusion proteins, receptor-based fusion proteins and others. Based on application, the market is segmented into ophthalmic conditions, autoimmune diseases, metabolic disorders and hematological diseases. Regarding the route of administration, the market is segmented into intravenous, subcutaneous, intravitreal and others. The report also focuses on regional segmentation, including North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.
The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance developments and discusses pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section featuring company profiles with detailed information about leading companies. The scope of the report focuses on Fc-fusion protein products.
Fusion proteins are an emerging area in protein engineering that combines an antibody with a desirable protein. The primary goals of fusion protein technology are to extend the duration of action and impart higher stability to protein drugs. These products have applications across therapeutic areas, including autoimmune, metabolic, oncologic, ophthalmic and cardiovascular conditions. The commercial success of many fusion proteins is driving the development of biosimilar versions of these proteins. Enbrel, Orencia, Trulicity, Eylea and Arcalyst were some of the best-selling fusion protein drugs in 2024.
Report Scope
The report provides an overview of the global fusion proteins market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented based on type, route of administration, application and region.According to type, the market is segmented into cytokine traps, peptide-based fusion proteins, receptor-based fusion proteins and others. Based on application, the market is segmented into ophthalmic conditions, autoimmune diseases, metabolic disorders and hematological diseases. Regarding the route of administration, the market is segmented into intravenous, subcutaneous, intravitreal and others. The report also focuses on regional segmentation, including North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.
The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance developments and discusses pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section featuring company profiles with detailed information about leading companies. The scope of the report focuses on Fc-fusion protein products.
Report Includes
- 92 data tables and 51 additional tables
- An overview of the global market for fusion proteins (genetically engineered recombinant therapeutics)
- Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the market size and revenue growth prospects, along with a corresponding market share analysis by ligand type, route of administration, application, and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
- Impact analysis of U.S. tariff laws, as well as use cases of AI adoption on the fusion proteins market
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Information on emerging trends and applications in diagnostics and research industries, ongoing research activities, newly approved products, and underlying clinical trials
- Identification of the major companies involved in the production and modification of fusion proteins, and analysis of the competitive landscape of the market
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Regeneron Pharmaceuticals Inc., Bristol Myers Squibb Co., Lilly, Amgen Inc., and Sanofi
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Pipeline Analysis
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Sustainability in the Fusion Proteins Market: An ESG Perspective
Chapter 8 Appendix
List of Tables
List of Figures
Companies Mentioned
- Amgen Inc.
- Astrazeneca
- Bayer Ag
- Bristol-Myers Squibb Co.
- Evive Biotech
- F. Hoffmann-La Roche Ltd.
- Kiniksa Pharmaceuticals
- Lilly Usa Llc.
- Merck & Co. Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Remegen
- Samsung Bioepis
- Sandoz Group Ag
- Sanofi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 127 |
| Published | October 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 36.3 Billion |
| Forecasted Market Value ( USD | $ 64.9 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
